GlassScriptPhysician profile
Bechara Mezher
NPI 1598751794
$10,674.35
in general payments reported to CMS, 2019-2025
39 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $416 · 2021: $1,328 · 2022: $1,449 · 2023: $2,272 · 2024: $1,934 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,483 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,482.99 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,809.09 | 2019-2025 | |
| Janssen Biotech, INC. | $1,103.81 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $759.98 | 2019-2024 | Xifaxan, Trulance |
| Celgene Corporation | $675.60 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $473.15 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $429.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $392.95 | 2019-2025 | Livdelzi |
| Ferring Pharmaceuticals INC. | $235.62 | 2021-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $228.75 | 2019-2024 | Dificid |
| Genzyme Corporation | $220.47 | 2022-2025 | |
| Madrigal Pharmaceuticals | $206.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $199.00 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $183.30 | 2019-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $177.82 | 2024-2025 | Voquezna |
| Medtronic, INC. | $174.41 | 2023 | Signia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $172.54 | 2024-2025 | Zenpep, Vowst |
| Novo Nordisk INC | $161.00 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $159.81 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $122.87 | 2021 | |
| Qol Medical, LLC | $120.04 | 2019-2022 | |
| Lilly USA, LLC | $94.30 | 2025 | Omvoh |
| Horizon Therapeutics Plc | $83.39 | 2023 | Krystexxa |
| Ardelyx, INC. | $81.18 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $71.51 | 2021-2025 | |
| Ambu INC. | $49.95 | 2020 | |
| Evoke Pharma, INC. | $38.95 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2025 | Iqirvo |
| Ethicon US, LLC | $29.73 | 2020-2021 | |
| Redhill Biopharma INC. | $24.62 | 2020-2022 | |
| Capsovision, INC. | $21.90 | 2023 | Capsocam Plus |
| Mallinckrodt Hospital Products INC. | $19.49 | 2020 | |
| Shionogi INC | $19.02 | 2019 | |
| Boston Scientific Corporation | $17.25 | 2021 | |
| Covidien LP | $15.81 | 2019 | |
| Shire North American Group INC | $15.50 | 2019 | |
| Celltrion USA INC. | $15.46 | 2025 | Vegzelma |
| Allergan, INC. | $14.12 | 2019 | |
| Braintree Laboratories, INC. | $13.34 | 2021 | |
| Alfasigma USA, INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bechara Mezher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.